Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 24, 2017

View Archived Issues

DPLG-3 promotes long-term cardiac allograft acceptance in mice

Wnt-FZD5 signaling circuit is a druggable target for RNF43-mutant pancreatic tumors

MAVS signaling in myeloid cells is critical for resistance to Ebola in murine models of infection

Detailed NETTER-1 results published for 177Lu-Dotatate in midgut neuroendocrine cancer

PfSPZ Vaccine protects against controlled malaria infection

Sunesis Pharmaceuticals provides update on lead programs

Merck KGaA and Domain Therapeutics announce license and collaboration agreement

Positive preliminary phase II data from children with CDKL5 genetic disorder

ADMA Biologics enters agreement to acquire assets from Biotest Pharmaceuticals

Macrocure completes merger with Leap Therapeutics

Peptide vaccine OCV-C02 safe and well tolerated in metastatic colorectal cancer patients

GeoVax begins new study of HIV vaccine

European orphan drug designation for Therabron's CG-367 for bronchiolitis obliterans syndrome

Aptose prioritizes development of its first-in class FLT3/BTK inhibitor

ViiV Healthcare UK presents novel HIV integrase inhibitors

Shionogi describes new high affinity nerve growth factor receptor inhibtors

FDA clears NantKwest's IND for phase I trial of haNK cell therapy

First patient enrolled in phase IIb CaLIPSO study of SNF-472

Bayer Pharma describes coagulation factor XIa and kallikrein B inhibitors

Resverlogix reports results from phase I trial of apabetalone in severe kidney impairment

Enteris BioPharma, Sanofi enter diabetes collaboration

Roche, Genentech identify novel RIP-1 inhibitors

Crinetics Pharmaceuticals discloses novel somatostatin sst2 receptor agonists

Eagle Pharmaceuticals completes NDA submission for Ryanodex

Immune Pharmaceuticals enters antibody collaboration with SATT Sud-Est

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...